Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban prophylaxis for PICC-related thrombosis in high-risk cancer patients
ChiCTR2000031133Phase 4Recruiting
- Sponsor
- Liuzhou People's Hospital
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in catheter-related thrombosis (CRT) (2 arms), sponsored by Liuzhou People's Hospital. Primary endpoints: Occurrence of venous thrombosis and Occurrence of major bleeding event. Started Mar 2020; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
catheter-related thrombosis (CRT)
Beyond the preview
Go deeper on ChiCTR2000031133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031133.